Developer docs
API playgroundTry for free, no card

Search company profiles

FibroFind

Full company profile

uuid0009zri

Namestring
FibroFind
Legal namestring
Fibrofind
Websiteurl
fibrofind.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

FibroFind is a UK-headquartered preclinical contract research organisation (CRO) that provides human-relevant preclinical testing services to global biopharmaceutical and biotech sponsors developing drugs for liver, kidney, and lung diseases. Founded in 2018 in Gateshead by Newcastle University scientists Professors Jelena Mann, Derek Mann, Fiona Oakley, and Dr. Lee Borthwick, the company addresses the well-documented translational gap in drug discovery, where fewer than 10% of drug candidates reach approval, by replacing surrogate preclinical models with evidence generated directly in viable human tissue.

The company's core offering is built on two integrated proprietary assets: a precision-cut tissue slices (PCTS) platform and patented bioreactor technology that together maintain native 3D cellular architecture and functional signalling pathways in ethically procured human liver, lung, and kidney tissue for extended study durations. These assets are delivered through four service modules — Target Identification and Validation, Lead Screening and Optimization, Pharmacology Studies, and Drug Safety Assessment — that produce decision-grade data intended to support IND-enabling submissions and to enable earlier go/no-go decisions. Operations are run from a purpose-built laboratory in Gosforth, Newcastle upon Tyne, and supported by advanced liquid handling robotics and AI-assisted data analysis.

FibroFind monetises through project-based professional services contracts under a quote-based pricing model, with revenue tied to bespoke study design and delivery for each biopharma client. The go-to-market is a single enterprise field sales motion targeting global biopharma sponsors directly. Quality, compliance, and data integrity are underpinned by ISO 9001, ISO 14001, Cyber Essentials Plus, GDPR-compliant data handling, and GLP/GxP-aligned scientific frameworks. In May 2025 the business was acquired by private equity firm Vespa Capital to fund its next phase of growth and global expansion, with a strengthened executive team including a CFO, CBO, Chair, and CCO installed alongside the founding scientists.

Short descriptiontext

FibroFind is a UK preclinical CRO that uses proprietary bioreactor technology and precision-cut human tissue slices (PCTS) to deliver human-relevant preclinical testing services — target validation, lead screening, pharmacology, and safety — to global biopharmaceutical sponsors developing drugs for liver, kidney, and lung diseases.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNewcastle Upon Tyne, United Kingdom
HQ citystring
Newcastle Upon Tyne
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
preclinical CRO services, drug development testing, tissue-based assays, human tissue models, biopharmaceutical research
Industry1 code
PRIMARYHLAGAOAJ
Preclinical, Toxicology & Translational Science Staffing FSP
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Scientific Staffing & Functional Service Providers (FSP)
NAICS code2 codes
  • Medical and Diagnostic Laboratories62151
  • Medical Laboratories621511
SIC code2 codes
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
Product category
Preclinical Drug Development Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Preclinical CRO Services
TypeProfessional Services
Description

Contract research organization providing expert-led study design, implementation and delivery services to biopharmaceutical companies for drug discovery and development programs. Revenue generated through project-based contracts for testing in human tissue.

fibrofind.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

FibroFind provides preclinical drug testing services for biopharmaceutical sponsors by culturing precision-cut slices of viable human liver, lung and kidney tissue inside proprietary bioreactors. Its integrated PCTS platform is used to deliver four service modules (target identification and validation, lead screening and optimization, pharmacology studies, and drug safety assessment) that generate human-relevant preclinical evidence to bridge the translational gap and inform go/no-go decisions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Extended study duration without loss of cellular diversity and tissue integrity
+1 more record
Product overview1 text field

FibroFind is a preclinical CRO operating as a unified platform combining proprietary bioreactor technology with precision-cut tissue slices (PCTS). The core technology consists of the PCTS Platform and Proprietary Bioreactor Technology, which work together to maintain viable human tissue for extended testing. The company offers four integrated service modules: Target Identification and Validation, Lead Screening and Optimization, Pharmacology Studies, and Drug Safety Assessment. This platform-plus-services architecture enables biopharma clients to access human-relevant preclinical testing, replacing simplified cell cultures and animal models with definitive biological data from human liver, lung, and kidney tissue.

Product and service1 record
1Precision-Cut Tissue Slices (PCTS) Platform
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Clinical Partnerships for Tissue Procurement
Strategic tierCoreTypeOthers
Description

Established clinical partnerships ensuring ethical procurement of viable human liver, lung and kidney tissue for use in PCTS platforms.

fibrofind.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

FibroFind was founded by Newcastle University scientists. The company maintains academic partnerships and translational research collaborations. Leadership includes academic, clinical and commercial insight.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Global preclinical CRO offering translational oncology and biospecimen services including patient-derived tissue models. Directly comparable to FibroFind as a translational preclinical CRO selling human-relevant evidence to biopharma, though it is much larger and more oncology-focused.

TypeBroad incumbent
Description

One of the largest global preclinical CROs offering safety assessment, discovery, and manufacturing services to biopharma. Comparable to FibroFind as a destination for outsourced preclinical drug development, though FibroFind's tissue-slice platform is a much narrower niche.

TypeBroad incumbent
Description

Global testing services group with substantial pharma and biopharma testing capabilities including preclinical and central laboratory services. Overlaps with FibroFind as a provider of laboratory-based drug development evidence to biopharma sponsors, but operates at vastly greater scale and breadth.

TypeBroad incumbent
Description

Global drug discovery and development CRO with deep preclinical and translational science capabilities, including the Cyprotex safety/toxicology franchise. Comparable to FibroFind in addressing the translational gap for biopharma R&D, though Evotec operates across the full drug discovery value chain rather than just tissue-based preclinical.

TypeDirect peer
Description

Preclinical CRO providing toxicology, safety assessment, and research models to biopharma. Closely comparable to FibroFind as a preclinical CRO serving biopharma sponsors, though Inotiv's core is animal-model toxicology rather than ex-vivo human tissue.

TypeBroad incumbent
Description

Global CRO/CDMO with extensive preclinical drug development services across discovery, toxicology, and bioanalysis. Overlaps with FibroFind as a comprehensive preclinical service provider to biopharma, though at materially larger scale and broader scope.

TypeEmerging player
Description

Provider of 3D microtissue (organoid) models for drug discovery and safety testing. Comparable to FibroFind as an emerging human-relevant preclinical platform aiming to replace animal models, though focused on organoid microtissues rather than precision-cut tissue slices.

TypeDirect peer
Description

Specialist in human tissue-based preclinical research, leveraging ethically sourced human tissues for drug discovery and safety assessment. Highly comparable to FibroFind given its use of viable human tissue for preclinical drug development services to biopharma.

TypeDirect peer
Description

Preclinical CRO offering a broad range of drug discovery services including target-based screening, biophysics, and safety pharmacology. Comparable to FibroFind as a smaller-scale preclinical CRO serving biopharma, though without the proprietary human-tissue platform.

TypeDirect peer
Description

Preclinical ADME/DMPK and safety/toxicology CRO serving biopharma, now part of Evotec. Comparable to FibroFind as a specialized preclinical services provider focused on derisking drug candidates before clinical development, though focused on in-vitro and in-silico ADME rather than human tissue slices.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

FibroFind

Preclinical Drug Development Servicesfibrofind.com

FibroFind is a UK preclinical CRO that uses proprietary bioreactor technology and precision-cut human tissue slices (PCTS) to deliver human-relevant preclinical testing services — target validation, lead screening, pharmacology, and safety — to global biopharmaceutical sponsors developing drugs for liver, kidney, and lung diseases.

What FibroFind does

FibroFind is a UK-headquartered preclinical contract research organisation (CRO) that provides human-relevant preclinical testing services to global biopharmaceutical and biotech sponsors developing drugs for liver, kidney, and lung diseases. Founded in 2018 in Gateshead by Newcastle University scientists Professors Jelena Mann, Derek Mann, Fiona Oakley, and Dr. Lee Borthwick, the company addresses the well-documented translational gap in drug discovery, where fewer than 10% of drug candidates reach approval, by replacing surrogate preclinical models with evidence generated directly in viable human tissue.

The company's core offering is built on two integrated proprietary assets: a precision-cut tissue slices (PCTS) platform and patented bioreactor technology that together maintain native 3D cellular architecture and functional signalling pathways in ethically procured human liver, lung, and kidney tissue for extended study durations. These assets are delivered through four service modules — Target Identification and Validation, Lead Screening and Optimization, Pharmacology Studies, and Drug Safety Assessment — that produce decision-grade data intended to support IND-enabling submissions and to enable earlier go/no-go decisions. Operations are run from a purpose-built laboratory in Gosforth, Newcastle upon Tyne, and supported by advanced liquid handling robotics and AI-assisted data analysis.

FibroFind monetises through project-based professional services contracts under a quote-based pricing model, with revenue tied to bespoke study design and delivery for each biopharma client. The go-to-market is a single enterprise field sales motion targeting global biopharma sponsors directly. Quality, compliance, and data integrity are underpinned by ISO 9001, ISO 14001, Cyber Essentials Plus, GDPR-compliant data handling, and GLP/GxP-aligned scientific frameworks. In May 2025 the business was acquired by private equity firm Vespa Capital to fund its next phase of growth and global expansion, with a strengthened executive team including a CFO, CBO, Chair, and CCO installed alongside the founding scientists.

FibroFind firmographics

Firmographics
Name
FibroFind
Legal name
Fibrofind
Website
https://fibrofind.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
FibroFind is a UK preclinical CRO that uses proprietary bioreactor technology and precision-cut human tissue slices (PCTS) to deliver human-relevant preclinical testing services — target validation, lead screening, pharmacology, and safety — to global biopharmaceutical sponsors developing drugs for liver, kidney, and lung diseases.
Ownership category
akta.pro rank

FibroFind industry classification

Industry
Product category
Preclinical Drug Development Services
NAICS
Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511)
SIC
Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAOAJ
Preclinical, Toxicology & Translational Science Staffing FSP
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Scientific Staffing & Functional Service Providers (FSP)

Keywords

  • Preclinical CRO services
  • Drug development testing
  • Tissue-based assays
  • Human tissue models
  • Biopharmaceutical research

Where FibroFind is headquartered

Location

Headquarters

HQ city
Newcastle Upon Tyne
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

FibroFind business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Preclinical CRO Services: Contract research organization providing expert-led study design, implementation and delivery services to biopharmaceutical companies for drug discovery and development programs. Revenue generated through project-based contracts for testing in human tissue.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

FibroFind product offering

Product offering

Core offering

FibroFind provides preclinical drug testing services for biopharmaceutical sponsors by culturing precision-cut slices of viable human liver, lung and kidney tissue inside proprietary bioreactors. Its integrated PCTS platform is used to deliver four service modules (target identification and validation, lead screening and optimization, pharmacology studies, and drug safety assessment) that generate human-relevant preclinical evidence to bridge the translational gap and inform go/no-go decisions.

Product overview

FibroFind is a preclinical CRO operating as a unified platform combining proprietary bioreactor technology with precision-cut tissue slices (PCTS). The core technology consists of the PCTS Platform and Proprietary Bioreactor Technology, which work together to maintain viable human tissue for extended testing. The company offers four integrated service modules: Target Identification and Validation, Lead Screening and Optimization, Pharmacology Studies, and Drug Safety Assessment. This platform-plus-services architecture enables biopharma clients to access human-relevant preclinical testing, replacing simplified cell cultures and animal models with definitive biological data from human liver, lung, and kidney tissue.

Differentiator

Problem solved

Functional benefit

Products and services

  • Precision-Cut Tissue Slices (PCTS) Platform

Quantifiable outcome

  • Extended study duration without loss of cellular diversity and tissue integrity
  • +1 more outcomes

Companies that use FibroFind

Customer profile

Segments1 record

Ideal customer profiles1 record

FibroFind technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

FibroFind partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Clinical Partnerships for Tissue ProcurementcoreOthersEstablished clinical partnerships ensuring ethical procurement of viable human liver, lung and kidney tissue for use in PCTS platforms.
  • Newcastle UniversitycoreStrategic or Co-development PartnerFibroFind was founded by Newcastle University scientists. The company maintains academic partnerships and translational research collaborations. Leadership includes academic, clinical and commercial insight.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

FibroFind competitors and assessment

Company assessment

Direct peers

  • Crown Bioscience: Global preclinical CRO offering translational oncology and biospecimen services including patient-derived tissue models. Directly comparable to FibroFind as a translational preclinical CRO selling human-relevant evidence to biopharma, though it is much larger and more oncology-focused.
  • Inotiv: Preclinical CRO providing toxicology, safety assessment, and research models to biopharma. Closely comparable to FibroFind as a preclinical CRO serving biopharma sponsors, though Inotiv's core is animal-model toxicology rather than ex-vivo human tissue.
  • AnaBios: Specialist in human tissue-based preclinical research, leveraging ethically sourced human tissues for drug discovery and safety assessment. Highly comparable to FibroFind given its use of viable human tissue for preclinical drug development services to biopharma.
  • Reaction Biology: Preclinical CRO offering a broad range of drug discovery services including target-based screening, biophysics, and safety pharmacology. Comparable to FibroFind as a smaller-scale preclinical CRO serving biopharma, though without the proprietary human-tissue platform.
  • Cyprotex (an Evotec company): Preclinical ADME/DMPK and safety/toxicology CRO serving biopharma, now part of Evotec. Comparable to FibroFind as a specialized preclinical services provider focused on derisking drug candidates before clinical development, though focused on in-vitro and in-silico ADME rather than human tissue slices.

Broad incumbents

  • Charles River Laboratories: One of the largest global preclinical CROs offering safety assessment, discovery, and manufacturing services to biopharma. Comparable to FibroFind as a destination for outsourced preclinical drug development, though FibroFind's tissue-slice platform is a much narrower niche.
  • Eurofins Scientific: Global testing services group with substantial pharma and biopharma testing capabilities including preclinical and central laboratory services. Overlaps with FibroFind as a provider of laboratory-based drug development evidence to biopharma sponsors, but operates at vastly greater scale and breadth.
  • Evotec: Global drug discovery and development CRO with deep preclinical and translational science capabilities, including the Cyprotex safety/toxicology franchise. Comparable to FibroFind in addressing the translational gap for biopharma R&D, though Evotec operates across the full drug discovery value chain rather than just tissue-based preclinical.
  • WuXi AppTec: Global CRO/CDMO with extensive preclinical drug development services across discovery, toxicology, and bioanalysis. Overlaps with FibroFind as a comprehensive preclinical service provider to biopharma, though at materially larger scale and broader scope.

Emerging players

  • InSphero: Provider of 3D microtissue (organoid) models for drug discovery and safety testing. Comparable to FibroFind as an emerging human-relevant preclinical platform aiming to replace animal models, though focused on organoid microtissues rather than precision-cut tissue slices.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

FibroFind social profiles

Digital presence

FibroFind compliance and trust

Trust signal

Compliance5 records

FibroFind financial estimates

Financial estimate

Revenue estimate

Valuation estimate

FibroFind leadership team

Management profile

Number of profiles

Profiles10 records

FibroFind funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

FibroFind M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FibroFind

What does FibroFind do?

FibroFind provides preclinical drug testing services for biopharmaceutical sponsors by culturing precision-cut slices of viable human liver, lung and kidney tissue inside proprietary bioreactors. Its integrated PCTS platform is used to deliver four service modules (target identification and validation, lead screening and optimization, pharmacology studies, and drug safety assessment) that generate human-relevant preclinical evidence to bridge the translational gap and inform go/no-go decisions.

Is FibroFind a public or private company?

FibroFind is a private company. It is classified as private equity controlled and is currently operating.

When was FibroFind founded?

FibroFind was founded in 2018. It employs 11 to 50 people.

Where is FibroFind based?

FibroFind is headquartered in Newcastle Upon Tyne, United Kingdom, in the Europe region.

How does FibroFind make money?

One revenue line is on record: preclinical CRO Services.

Who are FibroFind's main competitors?

Direct peers on record are Crown Bioscience, Inotiv, AnaBios, Reaction Biology and Cyprotex (an Evotec company). Broad incumbents are Charles River Laboratories, Eurofins Scientific, Evotec and WuXi AppTec. InSphero is listed as an emerging player.

Does FibroFind have an API?

No public API is recorded for FibroFind.

What industry is FibroFind in?

FibroFind's product category is Preclinical Drug Development Services. Its primary akta.pro industry code is HLAGAOAJ, Preclinical, Toxicology & Translational Science Staffing FSP. Its NAICS code is 62151 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals